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Abstract – The search for novel therapeutic options to cure alveolar echinococcosis (AE), due to the metacestode of
Echinococcus multilocularis, is ongoing, and these developments could also have a profound impact on the treatment
of cystic echinococcosis (CE), caused by the closely related Echinococcus granulosus s.l. Several options are being
explored. A viable strategy for the identification of novel chemotherapeutically valuable compounds includes whole-
organism drug screening, employing large-scale in vitro metacestode cultures and, upon identification of promising
compounds, verification of drug efficacy in small laboratory animals. Clearly, the current focus is targeted towards
broad-spectrum anti-parasitic or anti-cancer drugs and compound classes that are already marketed, or that are in
development for other applications. The availability of comprehensive Echinococcus genome information and gene
expression data, as well as significant progress on the molecular level, has now opened the door for a more targeted
drug discovery approach, which allows exploitation of defined pathways and enzymes that are essential for the par-
asite. In addition, current in vitro and in vivo models that are used to assess drug efficacy should be optimized and
complemented by methods that give more detailed information on the host-parasite interactions that occur during drug
treatments. The key to success is to identify, target and exploit those parasite molecules that orchestrate activities
essential to parasite survival.
Key words: Alveolar echinococcosis (AE), Echinococcus multilocularis chemotherapy, In vitro culture, Drugs,
Host-parasite interaction.
Résumé – Le traitement des échinococcoses : albendazole et mébendazole – quoi d’autre ? La recherche de
nouvelles options thérapeutiques curatives de l’échinococcose alvéolaire (EA), due au métacestode
d’Echinococcus multilocularis, est en progrès, et ses développements pourraient aussi avoir un profond impact sur
le traitement de l’échinococcose kystique (EK), due au cestode très proche Echinococcus granulosus s.l. Plusieurs
options sont explorées. Une stratégie efficace pour l’identification de composés nouveaux à activité
chimiothérapique est représentée par le criblage de médicaments sur le micro-organisme entier, utilisant des
cultures à grande échelle de métacestodes in vitro et, après identification de composés d’intérêt, la vérification de
leur activité chez des animaux de laboratoire. La recherche actuelle est clairement centrée sur les médicaments et
les classes de substances à activité antiparasitaire et anti-cancéreuse à large spectre qui sont déjà sur le marché ou
en cours de développement dans d’autres applications. La mise à disposition d’informations complètes sur le
génome d’Echinococcus et sur l’expression des gènes ainsi que des progrès significatifs à l’échelle moléculaire
ouvrent maintenant la porte vers une approche plus ciblée pour la découverte de nouveaux médicaments, en
permettant l’exploitation de voies métaboliques et d’enzymes indispensables au parasite. De plus, les modèles
actuels, in vitro et in vivo, actuellement utilisés pour confirmer l’efficacité d’un médicament, devraient être
optimisés et complétés par des méthodes qui permettraient d’obtenir des informations plus détaillés sur les
relations hôte-parasite qui surviennent au cours des traitements. La clé du succès est d’identifier, de cibler et
d’exploiter les molécules parasitaires qui orchestrent des activités essentielles à la survie du parasite.
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1. Introduction
The genus Echinococcus includes seven to nine described
species or genotypes [37], of which Echinococcus multilocu-
laris (the small fox tapeworm) is the most pathogenic, and
causes alveolar echinococcosis (AE) in humans. E. multilocu-
laris is largely restricted to the Northern hemisphere and
highest prevalence rates occur in Central Asia, Russia,
North-Western China, and parts of Europe and Japan. Echino-
coccus granulosus (the small dog tapeworm) causes cystic
echinococcosis (CE), occurs globally and represents the most
common species found in the Mediterranean area, Central Eur-
ope, South America, Africa and Central Asia. In addition, CE
exists as an imported disease in Western Europe and the USA
[7]. Both parasites cause life-threatening disorders of serious
public health and economic concern worldwide [62]. For AE
for instance, although a rare infection, the severity of the dis-
ease results in an estimated 600,000 disability-adjusted life
years (DALYs), which renders the impact of AE comparable
to tropical diseases such as leprosy, dengue and schistosomiasis
[7]. CE, but to some extent also AE, affects predominantly
resource-poor communities. For AE, present also in industrial-
ized countries with high economic standards, the number of
cases is underestimated by public health authorities in many
countries. For instance, the incidence rate for Germany, 0.07/
100,000 persons, is probably underestimated by a factor of
3–5 [17]. These factors contribute to the fact that the develop-
ment of new drugs for echinococcosis has not been a major
focus of the pharmaceutical industry. Both AE and CE are
neglected diseases, and emergence (or re-emergence), espe-
cially in developing countries, is likely, with an increasing eco-
nomic impact due to the need for livelong treatments [63].
Humans represent an aberrant intermediate host for these
parasites. Infection is acquired through the accidental ingestion
of parasite eggs, with serious health consequences for those
individuals in whom the disease develops. Eggs contain the
infectious larval oncosphere, which actively penetrates the
intestinal lining, and migrates via blood and lymphatic vessels
to the target sites, mostly the liver and lungs. There, these onc-
ospheres develop into the disease-causing metacestodes.
Within these metacestodes, protoscolex development takes
place in most intermediate hosts. If this type of infected inter-
mediate host is ingested by a suitable definitive host, the life
cycle is concluded [13]. Protoscolex development in humans
infected with E. multilocularis has only rarely been described.
Metacestodes are fluid-filled vesicles that are separated into
(i) an inner germinal layer representing the living and metabol-
ically active parasite tissue, and (ii) an outer, acellular compart-
ment known as the laminated layer, mediating the direct
physical contact with host immune and non-immune cells.
The distal part of the germinal layer, the tegument, is directly
associated with the inner surface of the laminated layer.
The tegument is characterized by microvilli-like extensions
termed microtriches, which protrude well into the matrix of
the laminated layer, and increase the resorbing surface of the
parasite. In addition, the germinal layer contains highly differ-
entiated cell types including connective tissue, muscle cells,
and glycogen storage cells, as well as many undifferentiated
cells [8]. The outer laminated layer is a carbohydrate-rich
structure that is synthesized by the parasite and secreted into
its peripheral entities, and which, in terms of thickness, is
much more prominent in E. granulosus s.l. metacestodes
[13]. In contrast to E. granulosus s.l. metacestodes, E. multiloc-
ularis metacestodes are not surrounded by a very prominent
host-derived adventitial layer. Instead, the parasite larva repre-
sents a multivesicular organism that reproduces asexually, by
exogenous formation and budding of daughter vesicles. This
process is often referred to as ‘‘progressive tumour-like
growth’’ [1], and leads to the formation of a large and hetero-
geneous parasitic mass consisting of mostly peripheral,
actively proliferating sites, and in many cases, centrally located
necrotic tissue. Release of germinal layer cells into the blood
or lymphatic vessels may lead to metastasis formation in other
organs [1, 8, 13, 33]. Spontaneous resolution of AE leading to
calcified lesions is possible, but it is not known how common
this is [1, 3, 8, 13, 33]. Mass screenings in endemic areas have
revealed that the number of established AE infections in
humans is far lower than the number of sero-positive humans
who had been exposed to the eggs of the parasite, but who
remained clinically healthy [19]. This indicated that in certain
individuals, innate or acquired immunity contributes to the
control of parasite development after infection. However, the
major focus of this review will be on drugs for the treatment
of Echinococcus infections, presenting progressively growing
and thus fully active metacestodes.
2. Advantages and pitfalls of the current
treatments of AE
Conventionally, treatment of echinococcosis relies on sur-
gery and/or chemotherapy depending on different factors such
as metacestode size and location, viability status, the interac-
tion between the expanding parasite and the adjacent host tis-
sue, bacterial and fungal infection, and, in the case of CE,
potential complications related to cyst rupture and spillage of
protoscoleces [4, 5, 20].
In CE, radical resection of the cyst mass represents the tra-
ditional treatment strategy and is, in many instances, accompa-
nied by chemotherapy. In addition, PAIR (puncture, aspiration,
injection, re-aspiration) is a technique introduced in the mid-
1980s. PAIR has been used in 700 patients, with promising
results [4, 5]. Indications and rules on how and when to apply
PAIR have been elaborated by an appropriate expert group [5].
For inoperable cases, chemotherapy with the benzimidazoles
albendazole, mebendazole and the heterocyclic pyrazinoiso-
quinoline derivative praziquantel remains the only options
[6, 14, 65, 66]. Adverse reactions against benzimidazoles
under long-term chemotherapy may occur, but can be avoided
by constant monitoring of drug serum levels (not possible in all
countries). Mebendazole and albendazole may induce
embryotoxic or teratogenic effects [14]. Praziquantel, exhibit-
ing high efficacy against protoscoleces and metacestodes in
animal experiments [6, 65, 66], was proposed to be applied
during the month prior to surgery alongside albendazole, since
this increased the number of human patients with non-
viable protoscoleces compared to therapy with albendazole
alone.
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For AE, the prognosis is to some extent different. If surgery
is carried out, it is always accompanied by chemotherapy using
benzimidazoles, which should be continued for at least 2 years
thereafter, and monitoring of patients should be continued for
10 years. Inoperable AE cases must undergo long-term chemo-
therapy, often life-long, which is based on albendazole and/or
mebendazole [40, 43]. Clinical studies have shown that benz-
imidazoles have significantly increased the 10-year survival
rate of inoperable or non-radically operated AE patients from
6–25% to 80–83% [7]. Despite this, albendazole and mebenda-
zole exhibit a parasitostatic rather than a parasitocidal effect.
In addition, hepatotoxicity occurs in some patients, and they
are left without any other option for treatment. Therefore,
recurrence rates after interruption of therapy are relatively
high, especially in those patients not followed up with appro-
priate prognostic tools [43, 60]. Thus, besides benzimidazoles,
other treatment options for AE are needed to improve the clin-
ical status of infected and diseased patients. Respective com-
pounds should exhibit better selectivity, a significantly
improved therapeutic window, and they should act as a parasit-
icidal rather than a parasitostatic.
3. Assessment of novel drugs and drug targets
to be explored for the treatment of AE
A substantial number of drugs have been evaluated for
their potential use against AE in vitro and, in many instances
also in vivo, employing a whole-organism based approach
[12, 13]. These include mostly broad-spectrum anti-infective
drugs, and drugs that inhibit cellular proliferation such as
anti-cancer compounds. Most reports, however, have been
anecdotal, since only relatively small numbers of compounds
could be evaluated at a given time, and large-scale screening
efforts were not possible. This has changed. The development
of large-scale in vitro techniques for the maintenance, propaga-
tion and axenic culture of E. multilocularis metacestodes
[2, 53] has now paved the way for whole metacestode drug
screening assays with a higher throughput. In addition, the cur-
rent genomic sequencing efforts [64, 69] have opened new ave-
nues, and conventional organism screening can now be
complemented by more targeted molecular genetic approaches.
3.1. Effects of anti-infective agents on
E. multilocularis metacestodes
Earlier animal experimentation studies in rodents demon-
strated parasitostatic effects of mitomycin C, piperazine and
quinolone derivatives, alkylaminoethers and propargylic alco-
hols, either at a lower level or comparable to benzimidazoles.
Other drugs such as praziquantel or alpha-difluoromethylorni-
thine were ineffective (reviewed in [12, 13, 48]). Nitazoxanide,
a broad-spectrum anti-parasitic drug belonging to the
thiazolide family, exhibited promising anti-echinococcal activ-
ities in vitro [28, 29]. The drug was also effective in experi-
mentally infected mice, and an albendazole-nitazoxanide
combination treatment was shown to be more effective than
albendazole alone [58, 59]. However, the drug did not keep
its promises: neither nitazoxanide monotherapy nor
albendazole-nitazoxanide combination therapies were effective
in human patients suffering from AE [21, 61]. However, a few
studies suggested that nitazoxanide may be an effective treat-
ment option in CE, particularly in patients with progressive dis-
ease who are receiving conventional therapy [38, 67, 68].
The in vitro efficacy of a series of compounds against
E. multilocularis metacestodes, including albendazole, arteme-
ther, caspofungin, itraconazole, ivermectin, methiazole,
miltefosine, nitazoxanide, rifampicin and trimethoprim/
sulfamethoxazole, was investigated by Reuter et al. [44], and
the authors found that albendazole, itraconazole, methiazole
and nitazoxanide effectively destroyed parasite vesicles
in vitro but effects were only parasitostatic. Amphotericin B
deoxycholate (cAMB), an anti-fungal compound, was shown
to effectively inhibit the growth of E. multilocularis metaces-
todes, first in vitro, and subsequently in human patients
in vivo [41–43]. A major limitation of cAMB is the intravenous
route of administration, which makes it unsuitable for pro-
longed use, except for salvage treatment. Also, the effect of
cAMB is only parasitostatic and the drug is nephrotoxic.
Nevertheless, prolonged application of cAMB for months to
years may be feasible in some cases, as side effects are mild
and serious organ damage does not appear to occur.
Stadelmann et al. [55] developed and validated a novel
E. multilocularis drug screening assay based on release of
the enzyme phosphoglucose isomerase (EmPGI) by parasites
that suffer from impaired viability due to drug treatment
in vitro. The increase in PGI activity measured in culture super-
natants correlated with the progressive degeneration and
destruction of metacestode tissue in a time- and concentra-
tion-dependent manner. Therefore, the PGI-assay enables
assessment of the degree of damage induced by drug treatment,
and enables structure-activity relationship analyses. In combi-
nation with the improved large-scale in vitro culture techniques
for metacestodes, this assay represents a highly useful and con-
venient tool to perform first-round in vitro tests on the efficacy
of large numbers of anti-parasitic compounds. Anti-malarial
compounds such as artemisinin and respectively derived perox-
ides (ozoids) [18, 28, 49], mefloquine and mefloquine enantio-
mers [23, 56], as well as pentamidine and dicationic
pentamidine-derivatives such as diamidines, arylimidamides
and diguanidino derivatives [26, 56] have been evaluated using
in vitro cultured metacestodes. Besides albendazole, other
benzimidazole derivatives have also been assessed. Of these,
triclabendazole was reported to exhibit profound in vitro
activity by Richter et al. [45], and fenbendazole, oxfendazole
(fenbendazole sulfoxide) and febantel were shown to be active
against E. multilocularis metacestodes in vitro and in the sec-
ondary mouse model [29]. Interestingly, TEM analysis of both
albendazole and fenbendazole-treated metacestodes revealed a
dramatic shortening/retraction of microtriches as a hallmark of
benzimidazole action, and as a consequence separation of the
acellular laminated layer from the cellular germinal layer
[16, 32]. Since TEM did not reveal any microtubule-
based structures within Echinococcus microtriches, this effect
cannot be explained by the previously described mechanism
of action of benzimidazoles targeting b-tubulin. Therefore,
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benzimidazoles must interact with additional targets that have
not yet been identified [29].
In terms of in vivo efficacy, the anti-malarial mefloquine
and the thiophene-di-guanidino compound DB1127 were
shown to exhibit promising properties. Intraperitoneal applica-
tion of mefloquine in secondarily-infected mice (25 mg/kg,
twice a week) resulted in a reduction in parasite weight that
was similar to what was obtained with orally applied albenda-
zole (200 mg/kg/day), but oral application of the same dose
was not successful [23]. However, more recent studies have
now shown that the success of oral application of mefloquine
in mice is dose-dependent, and at a higher dosage, results in
a reduction in parasite weight comparable to what is achieved
by albendazole treatment (manuscript in preparation). Simi-
larly, intraperitoneal application of DB1127 in secondarily
infected mice reduced the parasite weight, however, oral appli-
cation of the drug had no effect. Although these are promising
results, it is important to keep in mind that DB1127 is an
experimental compound, and there is no data on bioavailability,
pharmacokinetics and toxicity in animals. In addition, meflo-
quine treatment in humans has a variety of documented
adverse side effects including neurotoxicity and elevation of
liver enzymes. In conjunction with albendazole, the latter
could pose a serious clinical problem. Nevertheless, inclusion
of mefloquine in an albendazole-based treatment regimen at
a prophylactic dosage in addition to continuous albendazole
treatment might be an intriguing new concept.
The anti-echinococcal properties of the antibiotic macro-
lide clarithromycin were identified via an in silico approach
[32]. Clarithromycin inhibits protein synthesis in bacteria by
binding to the nascent peptide exit tunnel on the ribosome near
the peptidyltransferase centre of large subunit rRNA. Higher
eukaryotes carry a guanine at position 2058 of both cytoplas-
mic and mitochondrial rRNAs, and this modification at this
position had been demonstrated to confer the resistance of
eukaryotic cells to macrolide antibiotics. In contrast, the mito-
chondrial rRNA of E. multilocularis carries an adenine at
sequence position 2058, which predicts susceptibility as in bac-
teria [46], while the nucleus-encoded rRNA is characterized by
a guanine at 2058. Upon in vitro culture of E. multilocularis
metacestodes with clarithromycin, parasites, as expected,
exhibited severely impaired growth characteristics and mor-
phology in a dose-dependent manner. Adult worms were also
severely affected, lost their motility and displayed morpholog-
ical alterations such as shortening and constriction of proglott-
ids and increased vacuolization [32]. However, these promising
results were never followed-up by appropriate in vivo studies.
The availability of comprehensive and detailed genome
and transcriptome information on Echinococcus and other ces-
tode parasites [64, 69] has opened the door for the identifica-
tion of drug targets by affinity chromatography followed by
MS-based sequencing, and potentially also for reverse genetics
by overexpressing or silencing genes of interest. After the
development of procedures to perform transient transfections
of primary cells of E. multilocularis [52], the successful estab-
lishment of RNAi in primary E. multilocularis cell cultures
using three E. multilocularis genes, emgapdh, em14-3-3 and
emelp was achieved [54]. The expression of all three genes
was knocked down by RNAi on the transcriptional and
translational level. In future work, this promising technology
will be employed to validate drug targets or other essential pro-
teins in the context of the immunological host-parasite
interaction.
3.2. Drugs inhibiting cancer cell proliferation
E. multilocularis metacestodes and malignant tumours
share some distinct features, namely their capacity for contin-
uous cell proliferation, the potential to modulate immune
response, the secretion of proteolytic enzymes in order to reach
their target sites or organs, induction of angiogenesis, overex-
pression of 14-3-3 proteins, and the capacity of metastasis for-
mation. These similarities suggested that anti-proliferative
compounds could also affect E. multilocularis metacestodes.
Conversely, and not surprisingly, many compounds that exhibit
broad-spectrum anti-infective activities (including artemisi-
nins, mefloquine and nitazoxanide-derivatives) also show
clearly elevated toxicity in proliferating cells [22, 35].
One of the first anti-cancer drugs that had been investigated
for its potential use against AE is doxorubicin, or hydroxyld-
aunorubicin, a DNA-interacting drug used widely in the treat-
ment of a wide range of cancers. The compound was bound to
polyisohexylcyanoacrylate nanoparticles (a colloidal biode-
gradable drug carrier) and applied in E. multilocularis-infected
mice. This resulted in a reduced mass of metacestode tissue in
the liver and reduced viability of this metacestode. In contrast,
free doxorubicin or unbound nanoparticles had no anti-
parasitic activity [30]. However, due to the massive side effects
that are generally encountered by doxorubicin, this treatment
approach was not further pursued.
Another class of anti-tumour agents with proven anti-
parasitic activities includes isoflavonoids. Isoflavonoids are
substances formed by plant tissue in response to physiological
stimuli such as infectious agents. Genistein, a major compo-
nent of soya, inhibits growth and metastasis formation of a
number of cancer cell lines (breast, prostate, skin, colon).
Genistein also stimulates the synthesis of TGF-b, which itself
inhibits cancer cell proliferation [34]. Besides other targets,
genistein acts on a number of signalling pathways, by function-
ing as a kinase inhibitor (tyrosine-kinase, MAP kinase, ribo-
somal S6 kinase), but also binds the oestrogen receptor-b,
and thus exerts unfavourable effects on long-term treatment
[39]. However, genistein, as well as a number of derivatives
such as Rm6423 that do not meet the steric requirements to
bind to the oestrogen receptor-b were also highly effective
against E. multilocularis metacestodes in vitro, as well as
against E. granulosus s.l. metacestodes and protoscoleces
[36]. The molecular basis of the efficacy of genistein and its
derivative Rm6423 has not been elucidated, but these com-
pounds could interfere in signalling, for instance through inhib-
iting the tyrosine kinase activity associated with the epidermal
growth factor receptor identified in E. multilocularis [51].
However, the anti-echinococcal efficacy of isoflavonoids has
not been assessed in vivo to date.
An endogenous metabolite of oestrogen with both
anti-angiogenic and anti-tumour effects, 2-methoxyestradiol
(2-ME) was shown to induce severe damage toE.multilocularis
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metacestodes in vitro in a dose-dependent manner [50].
In contrast, 2-ME-treatment of experimentally infected mice
did not result in a reduction in parasite weight compared to
the non-treated controls. Best results were achieved with a
treatment using a combination of 2-ME and albendazole,
which leads to a substantial, but not statistically significant,
reduction in parasite weight compared to albendazole
treatment alone.
Gelmedin et al. [10] identified pyridinyl imidazoles as
ATP-competitive inhibitors of a p38-like mitogen-activated
protein kinase (MAPK) of E. multilocularis by adding them
to in vitro cultures, and demonstrating death of parasite vesi-
cles at concentrations that did not affect cultured mammalian
cells. Imatinib, a tyrosine-kinase inhibitor used in the treatment
of multiple cancers, most notably chronic myelogenous leukae-
mia, was reported to be highly effective in killing Echinococ-
cus stem cells, metacestodes and protoscoleces in vitro.
At concentrations as low as 10 lM, imatinib significantly
inhibited the formation of metacestodes from parasite stem
cells, inactivated 50% of vesicles after 7 days, and induced
morphological alterations in the metacestode upon short-term
treatment [11]. Another kinase inhibitor, BI 2536, a Polo-like
kinase inhibitor that has been tested in clinical trials against
cancer, significantly blocked the formation of metacestode
vesicles from cultivated Echinococcus germinative cells at
concentrations as low as 20 nM [62]. Furthermore, low
concentrations of BI 2536 eliminated the germinative cell
population from mature metacestode vesicles in vitro, yielding
parasite tissue that was no longer capable of proliferation.
As germinative cells are decisive for parasite proliferation
and metastasis formation within the host, BI 2536 and related
compounds are very promising compounds to complement
benzimidazoles in AE chemotherapy [47].
NTZ, previously introduced as an anti-infective drug, also
inhibited the proliferation of colon cancer cells in vitro, and
Müller et al. [35] have shown that this happens by interfering
with, and inhibiting, the activity of glutathione-S-transferase
(GST) class p, an isoform overexpressed in many proliferating
cells. In E. granulosus s.l. and E. multilocularis, the only GSTs
characterized so far, have some sequence homologies to the
mammalian class l [9, 31]. The catalytic properties of recom-
binant GST of E. multilocularis, however, exhibit higher simi-
larities to mammalian classes a and p, with, especially, a high
conjugating activity on ethacrynic acid, another anti-cancer
drug [31]. In principle, GSTs may have two opposite effects
on drugs, namely by inactivating drugs or by activating ineffec-
tive prodrugs. Especially the latter effects have been employed
as an anti-cancer drug strategy and may be further
developed against AE. In addition, these studies suggest that
Echinococcus GST should be further investigated, and vali-
dated, as a potential drug target.
Organometallic ruthenium complexes have been developed
as a replacement for the highly toxic cisplatin for the treatment
of cancer. Two series of g(6)-arene ruthenium(II) phosphite
complexes were prepared, characterized and evaluated
in vitro for their toxic potential against E. multilocularis met-
acestodes, with promising results [25]. Animal experimenta-
tion is, however, still pending.
More recently, screening of a commercially available FDA-
approved drug library comprised of over 400 drugs that are
currently in use against different diseases resulted in the iden-
tification of the profound activity of bortezomib, a proteasome
inhibitor used as an anti-cancer drug, against E. multilocularis
metacestodes. Detailed studies on the activity of bortezomib in
Echinococcus showed that indeed the proteasome represents a
promising drug target that should be exploited in more detail in
the future [57].
Conversely to inhibiting metacestode proliferation, cyto-
static drugs can also exhibit effects that lead to increased pro-
liferation and growth of E. multilocularis metacestodes in vivo
[15]. It was shown that in vitro exposure of metacestodes to
methotrexate and subsequent infection of mice with treated
parasites lead to massive growth and increased parasite prolif-
eration, while navelbine and vincristine treatment had no clear
effects. In this study, magnetic resonance imaging was used to
monitor the effects of the drugs on growth progression [15].
4. Future developments
As outlined above, a number of potentially beneficial drugs
and drug targets have now been identified, which could be fur-
ther exploited to develop novel therapeutic treatment options.
However, in order to identify compounds that will actually
make it into the clinics, the currently employed tools for the
identification and assessment of drug efficacy in vitro and
in vivo need to be improved, both in terms of throughput as
well as quality of the read-out.
In terms of in vitro assessment, the currently used PGI
screening assay [38] has proven very valuable, but it also has
some limitations: (i) the assay exhibits a certain degree of var-
iability, depending on the age and size of metacestodes, and
ideally repetitions are required with different batches of meta-
cestode cultures to obtain clear-cut results; (ii) the assay is rel-
atively labour-intensive and requires multiple pipetting steps;
(iii) while 96 well format is possible, 24 well format is more
reliable; (iv) compounds interfering with the PGI enzyme reac-
tion could potentially disturb the assay; (v) the assay picks up
metacestode damage but does not necessarily measure loss of
viability; and (vi) if metacestodes are damaged by mechanisms
that do not lead to PGI release within the given time frame of
treatment (such as with benzimidazoles [45, 55]), false-nega-
tive results can occur. To overcome pitfalls (i)–(iv), screening
assays based on E. multilocularis cell cultures could provide
a worthwhile alternative by increasing throughput of drug
screening activities. In addition, to improve pitfalls (v) and
(vi), other assays that deliver a more precise read-out on met-
acestode viability should be developed to increase the chances
of picking up drugs that hit essential targets and act as
parasiticidals.
There is also ample room for improvement and refinement
for the in vivo assessment of drug efficacy in murine AE. In an
ideal world, experiments should be carried out in mice infected
orally with E. multilocularis eggs. However, these are not
always available, thus in most cases the secondary infection
model (intraperitoneal injection of metacestode tissue) is used.
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Corresponding experiments and drug applications often take
several months, and optimization of treatment parameters (stop
or continuation, dosage adjustments) during this period is not
possible. In addition, the classical read-out (determination of
parasite weight) has a high degree of variability, due to the fact
that metacestodes are often intermingled and/or encapsulated
by connective tissue, or even spread to neighbouring organs,
and thus the degree of encapsulation has a major impact on
parasite weight. Thus, large group sizes of 8–10 animals are
required. To overcome this problem, periodic ultrasound mon-
itoring of mice under treatment could provide additional infor-
mation on location, parasite mass, degree of encapsulation and
organ involvement during the experimental period, and this
could allow informed decisions on treatment interruption and
dosage adjustments. A first step in this direction has been
the development of a subcutaneous murine infection model
for AE, which allowed a much more precise assessment of par-
asite mass, and thus drug efficacy, compared to the classical
intraperitoneal infection model [27].
Another method of refinement concerns the drug applica-
tion: compounds that are routinely applied by gavage on a daily
basis can often be emulsified in honey, and we found that mice
will take them up voluntarily, which significantly reduces the
stress level during the treatment period [24]. Compared with
gavage, voluntary ingestion of a drug in honey is more rapid,
less stressful to the animal and less technically demanding
for the administrator. As shown for albendazole, drug metabo-
lism was not affected by this procedure, but this will have to be
evaluated for other compounds [68].
5. Conclusions
The search for improved treatment options for echinococ-
cosis based on novel compounds is ongoing. The significant
advances in our knowledge on Echinococcus biology at the
molecular level, and the development of reliable tools for
improved in vitro culture techniques and genetic approaches
have now facilitated the search for novel and potentially suit-
able chemotherapeutical tools that will provide infected
patients with additional treatment options. A major concern
is funding, since although compounds are readily being made
available from interested parties, drug-screening efforts need to
be financed. It is important to increase public awareness about
the impact of AE and CE on society, in order to generate suf-
ficient resources to actually carry out the research and studies
on chemotherapeutically promising compound classes.
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